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Background: Brainstem metastases represent an uncommon clinical presentation that is associated with a poor
prognosis. Treatment options are limited given the unacceptable risks associated with surgical resection in this
location. However, without local control, symptoms including progressive cranial nerve dysfunction are frequently
observed. The objective of this study was to determine the outcomes associated with linear accelerator-based
stereotactic radiotherapy or radiosurgery (SRT/SRS) of brainstem metastases.
Methods: We retrospectively reviewed 38 tumors in 36 patients treated with SRT/SRS between February 2003 and
December 2011. Treatment was delivered with the Cyberknife™ or Trilogy™ radiosurgical systems. The median age
of patients was 62 (range: 28–89). Primary pathologies included 14 lung, 7 breast, 4 colon and 11 others. Sixteen
patients (44%) had received whole brain radiation therapy (WBRT) prior to SRT/SRS; ten had received prior SRT/SRS
at a different site (28%). The median tumor volume was 0.94 cm3 (range: 0.01-4.2) with a median prescription dose
of 17 Gy (range: 12–24) delivered in 1–5 fractions.
Results: Median follow-up for the cohort was 3.2 months (range: 0.4-20.6). Nineteen patients (52%) had an MRI
follow-up available for review. Of these, one patient experienced local failure corresponding to an actuarial 6-month
local control of 93%. Fifteen of the patients with available follow-up imaging (79%) experienced intracranial failure
outside of the treatment volume. The median time to distant intracranial failure was 2.1 months. Six of the 15
patients with distant intracranial failure (40%) had received previous WBRT. The actuarial overall survival rates at
6- and 12-months were 27% and 8%, respectively. Predictors of survival included Graded Prognostic Assessment
(GPA) score, greater number of treatment fractions, and higher prescription dose. Three patients experienced acute
treatment-related toxicity consisting of nausea (n = 1) and headaches (n = 2) that resolved with a short-course of
dexamethasone.
Conclusion: SRT/SRS for brainstem metastases is safe and achieves a high rate of local control. We found higher
GPA as well as greater number of treatment fractions and higher prescription dose to be correlated with improved
overall survival. Despite this approach, prognosis remains poor and distant intracranial control remains an issue,
even in patients previously treated with WBRT.
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Brain metastases develop in 20-40% of cancer patients
representing the most common manifestation of intracra-
nial malignancy [1]. These lesions can result in devastating
clinical consequences, particularly when they involve brain-
stem structures. Options for management of brainstem
metastases include whole brain radiation therapy (WBRT)
or SRT/SRS [2-4]. Surgical access, however, is often limited
in cases of brainstem metastases. In regards to WBRT,
there are concerns regarding cognitive effects as well as the
potential for durable local control in radioresistant tumors
such as renal cell or melanoma metastases. The safety of
SRT/SRS for brainstem metastases remains an important
question given the proximity to critical structures and po-
tential for treatment-related toxicity [5]. Studies assessing
the safety and efficacy of SRT/SRS for metastases to the
brainstem have been accumulating from different institu-
tions over the past decade [6-15]. In this study, we analyze
our institution’s experience using linac-based SRT/SRS for
the treatment of brainstem metastases to determine the
safety and efficacy of this treatment approach.
Methods
Patient population
Patient characteristics are presented in Table 1. We
retrospectively analyzed the outcomes of 36 patients
with 38 brainstem metastases who received SRT/SRS
treatment between February 2003 and December 2011
at the University of Pittsburgh Cancer Institute. The me-
dian age was 62 (range: 28–89), seventeen patients were
male and 19 patients were female. Of the lesions treated,
25 were located in the pons, 11 in the midbrain, and 2
in the medulla. Primary pathologies included 14 lung, 7
breast, 4 colon and 11 others. Sixteen patients (44%) had
received WBRT prior to SRT/SRS; ten (28%) had
received prior SRT/SRS to a different site. At the time of
their SRT/SRS consult, 25 patients (69%) were symp-
tomatic with neurological complaints including weak-
ness, headaches and ataxia. Furthermore, 29 of the
patients (76%) had other distant brain metastases at the
time of their consult. Karnofsky Performance Status
(KPS), Graded Prognostic Assessment (GPA) [16] and
Recursive Partitioning Analysis (RPA) [17] were deter-
mined for all of the patients.
Simulation and planning
Each patient was comfortably positioned on the compu-
terized tomography (CT) simulation table and a custom
relocatable thermoplastic mask was fabricated. A thin-
slice high resolution CT with intravenous contrast was
then obtained while the patient was immobilized. The
acquired images were then transferred to the treatment
planning workstation and fused with pre-treatment thin-
slice (1.2 mm) contrast enhanced spoiled gradientrecalled acquisition in steady state (SPGR) sequence
magnetic resonance imaging (MRI) utilizing commer-
cially available fusion software. The tumor volume and
any surrounding critical structures were manually deli-
neated by a radiosurgical team inclusive of a radiation
oncologist, a medical physicist, and a neurosurgeon. The
planning target volume was defined as the contrast-
enhancing tumor with no margin. Dose volume histo-
grams were calculated for the target volume and nearby
critical structures and were utilized to select the optimal
treatment plan. An ideal SRT/SRS plan provided cover-
age of at least 95% of the prescription dose to the PTV
while sparing surrounding organs at risk. If surrounding
organs at risk were deemed to be at excess risk for tox-
icity, a plan with lower PTV coverage was accepted.
Radiosurgery was performed using CyberKnifeTM Ro-
botic Radiosurgery System (Accuray, Inc., Sunnyvale,
CA) for 34 lesions and TrilogyTM Radiosurgery System
(Varian Medical Systems, Palo Alto, CA) for 4 lesions,
one of which was treated in 3 fractions.
Follow-up
Follow-up neurologic examination and MRI (or CT
scanning if ineligible for MRI) were performed at
2 months after SRT/SRS, every 2–3 months for the 1st
year, and at 3 to 6 monthly intervals thereafter. Imaging
was performed to assess changes in tumor size, to iden-
tify the development of any new tumors, and to evaluate
the risk of peri-tumoral reactive swelling. A significant
change in tumor size was defined as either an increase
or decrease of 2 mm in the contrast enhancing dimen-
sions in any single plane of the tumor in accordance
with our institutional definition of treatment response.
Distant failure was defined as the development of new
brain metastases outside the original SRT/SRS treatment
volume. Of the patients who had available follow-up
data, the presence of extracranial progression was also
assessed.
Statistics
Survival time was computed from the commencement
of SRT/SRS. Survival curves and median survival were
calculated using the Kaplan–Meier method. Factors
affecting survival from the time of brain metastasis diag-
nosis were determined using the Cox proportional
hazards model. All statistical tests were carried out using
SPSS Version 15.0 (SPSS, Chicago, IL). The project was
reviewed and approved by the University of Pittsburgh
Institutional Review Board.
Results
Thirty-eight tumors in 36 patients were treated. The me-
dian tumor volume was 0.94 cm3 (range: 0.01-4.2) with
a median prescription dose of 17 Gy (range: 12–24)
Table 1 Characteristics of patients with brainstem
metastases
Characteristic Value
Patients (F/M), n 36, (17/19)
Lesions, n 38
Median age (range), y 62 (28-89)
Primary Malignancy, n (%)
Lung 14 (39%)
Breast 7 (19%)
Colon 4 (11%)
Other 11 (31%)
Symptoms, n (%) 25 (39%)
Headache 8 (22%)
Weakness 6 (17%)
Ataxia 7 (19%)
Visual Changes 6 (17%)
Median KPS score (range) 80 (60-90)
Median GPA score (range) 1.5 (0-3.5)
RPA class, n (%)
I 4 (11%)
II 30 (83%)
III 2 (6%)
Number of intracranial metastases
at time of SRS, n (%)
1 9 (24%)
2 to 4 23 (61%)
>4 6 (16%)
Median interval between primary
diagnosis and SRS (range), mo
16 (1-190)
Median tumor volume (cc), range 0.94 (0.01-4.2)
Location of treated brainstem
metastasis, n (%)
Midbrain 11 (29%)
Pons 25 (66%)
Medulla 2 (5%)
WBRT for brain metastases before SRS, n (%) 18 (47%)
Median SRS dose (range), Gy 17 (12-24)
Treatment Fractions, n (%)
1 20 (56%)
2 2 (6%)
3 13 (36%)
5 1 (3%)
Treatment Modality, n (%)
Cyberknife 34 (89%)
Trilogy 4 (11%)
Leeman et al. Radiation Oncology 2012, 7:107 Page 3 of 7
http://www.ro-journal.com/content/7/1/107delivered in 1–5 fractions prescribed to the 80% isodose
line. The median minimum tumor dose was 15.6 Gy and
the median maximum tumor dose was 20.25 Gy. Of the
36 patients, 20 were treated with a single fraction (56%),
2 in two fractions (6%), 13 in 3 fractions (36%) and 1 in
5 fractions (3%). Dose selection and fractionation were
based on various factors including tumor volume, loca-
tion, timing and total dose of prior radiation therapy.
Local control
Median follow-up from time of SRT/SRS for the co-
hort was 3.2 months (range: 0.4-20.6). Nineteen
patients (52%) had an MRI follow-up available for re-
view. Of these, one patient experienced local failure
corresponding to an actuarial 6-month local control of
93% (Figure 1). With only one local failure, significant
predictors of local control could not be ascertained.
Intracranial control
Fifteen of the patients with available follow-up imaging
(79%) experienced intracranial failure outside of the
treatment volume. Of these fifteen patients, six (40%)
had undergone prior WBRT, although WBRT was not
found to be significant predictor of intracranial control
(p = 0.09) The median time to distant intracranial failure
was 2.1 months with a 6-month intracranial control rate
of 21% (Figure 2).
Overall survival
The actuarial overall survival rates at 6- and 12-months
were 27% and 8%, respectively (Figure 3). Predictors of
survival included Graded Prognostic Assessment (GPA)
score, number of treatment fractions, and higherFigure 1 Kaplan-Meier analysis of local control after SRT/SRS
treatment of a brainstem metastasis. The 6 month and 12 month
actuarial control rates were 93%.
Figure 2 Kaplan-Meier analysis of intracranial control after
SRT/SRS treatment of a brainstem metastasis. The median time
to distant intracranial failure was 2.1 months.
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vival (p = 0.009) as patients with a GPA score of 0–1 had
a median survival of 2.1 months and patients with a
score of 1.5-2.5 had a median survival of 4.2 months.
There were only 3 patients with GPA≥ 3 with a median
survival of 1 month, partly because one patient had a
rapid decline in his neurological condition and went to
hospice after receiving only 2 out of 3 prescribed frac-
tions. RPA was not found to be a predictor of overall
survival as 30/36 patients were RPA class II. Number of
fractions was also found to be a significant predictor of
overall survival (p= 0.01); patients treated with a singleFigure 3 Kaplan-Meier analysis of overall survival after SRT/SRS
treatment of a brainstem metastasis. Median overall survival was
found to be 3 months.fraction had a median survival of 2.2 months while
patients treated in 3 fractions had a median survival of
4.8 months. Similarly, prescription dose was found to be a
predictor of overall survival (p= 0.01); patients treated
with a prescription dose of <20 Gy had a median survival
of 2.1 months while those treated with≥ 20 Gy survived a
median of 4.8 months. Of the twenty patients with known
cause of death, 8 were determined to have died from
causes related to central nervous system (CNS) dysfunc-
tion while 12 died from extracranial causes.
Toxicity
Three patients experienced acute treatment-related tox-
icity consisting of nausea (n = 1) and headaches (n = 2)
that resolved with a short-course of dexamethasone. No
grade 3 or higher toxicities were observed.
Discussion
In this study, we have assessed the efficacy of linac-based
SRT/SRS for the treatment of metastases located in the
brainstem and determined rates of local control, intracra-
nial control and overall survival. Furthermore, we have
identified factors that are associated with improved overall
survival within this subset of patients that may be useful
for stratification of patients with brainstem metastases
who are being considered as candidates for SRT/SRS.
Prior studies examining SRS for brainstem metastases
are summarized in Table 2. In 1999, Huang et al. [8] first
assessed SRS for brainstem metastases using Gamma
Knife technology (Elekta Medical System, Stockholm,
Sweden). With a median prescription dose of 16 Gy and
a mean tumor volume of 1.1 mL, they found a local con-
trol rate of 95% and a median survival of 9 months with
a 27% rate of adverse events. Only active extracranial
disease was found to be a predictor of poor survival.
Koyfman et al. [11] again used Gamma Knife with a me-
dian prescribed dose of 15 Gy for brainstem metastases
and found a median survival of 5.8 months with a local
control rate of 85% with a 12% complication rate. Lower
KPS, larger tumor volume, lower GPA and lower Score
Index for Radiosurgery in Brain Metastases (SIR) [18]
were all associated with shorter survival. Using linac-
based SRS with a median prescribed dose of 15 Gy,
Hatiboglu et al. [7] found a median survival of 4.2 months
with a local control rate of 76%. They determined that lar-
ger tumor volume and male sex were associated with
poorer survival. Their rate of adverse events was 20%.
Our data further refine the findings of other authors
as well as provide new and important considerations in
optimizing outcomes. The data demonstrate that SRT/
SRS for brainstem metastases provides effective local
control (93%) with failure documented in only one out
19 lesions with available follow-up imaging. This is con-
sistent with the reports mentioned above and findings
Leeman et al. Radiation Oncology 2012, 7:107 Page 5 of 7
http://www.ro-journal.com/content/7/1/107from other institutions that demonstrate local control
rates of 92-100% [6,8,9,12,15] after SRS treatment of a
brainstem metastasis. Others have published local
control rates that have been slightly lower, ranging from
76-85% [7,10,11,13,14]. This variation is potentially
attributable to differences in the radiographic definition
of local control, which is not often reported.
We found the median overall survival of patients trea-
ted with SRT/SRS for brainstem metastases to be
3 months, somewhat less than others who have reported
median survival in the range of 9–12 months after SRS
for brainstem metastases [6,8,10,14]. The poor survival
in our cohort may be the result of advanced and pro-
gressive extracranial disease at the time of presentation;
the median GPA score was 1.5 and only 4 patients were
classified as RPA class I. Furthermore, of the 20 patients
with a known cause of death, 12 (60%) died due to sys-
temic causes that were not related to brain metastases
indicating that the burden of extracranial disease in our
cohort was relatively high. Importantly, we do not re-
quire that patients have controlled extracranial disease
to qualify for SRT/SRS treatment. This difference may
account for much of the discrepancy in overall survival
observed between our study and reported findings.
Other studies of SRS for brainstem metastases have
demonstrated a relationship between active extracranial
disease and shorter survival [8,14].
We found higher GPA score to be correlated positively
with increased survival as has also been demonstrated
by Koyfman et al. [11]. Specifically, patients with a GPA
score of 1.5-2.5 survived twice as long as patients with a
score of 0–1. We did not have sufficient patients with
GPA> 2.5 for adequate assessment above this threshold,
again pointing to the advanced nature of disease in our
patient pool. We were unable to assess RPA as a prog-
nostic factor as too few of our patients were classified as
RPA I or RPA III. Identification of factors associated
with prolonged survival is critical for selection of appro-
priate treatment candidates, especially given the cost of
radiosurgical techniques and potential for toxicity.
A new finding not previously reported is the observa-
tion that a greater number of fractions and higher
prescription dose were also found to be positively corre-
lated with overall survival. Patients treated with ≥20 Gy
in 3 fractions survived significantly longer than patients
treated with <20 Gy in 1 fraction. This is likely due to
the fact that patients with smaller lesions or advanced
extracranial disease are preferentially treated with single
fraction regimens whereas patients with larger lesions or
well-controlled systemic disease receive fractionated
regimens. Lorenzoni et al. [15] found a similar correl-
ation between higher prescription dose and prolonged
survival. Additionally, Vogelbaum et al. [19] have
demonstrated that with the use of the RTOG 90–05dosing scheme, smaller tumors treated with 24 Gy were
better controlled than larger tumors treated with a smal-
ler dose.
Despite concerns surrounding radiosurgical treatment
of the brainstem, our rate of acute adverse effects was
quite low (8%). Furthermore, we found no high grade
toxicity or new neurological deficits, only headache and
nausea that resolved with a short course of steroids. This
is in keeping with several other studies that have demon-
strated complication rates in the range of 0-10% [6,9,12-
15]. The median follow-up time in this study was just
3.2 months due to the poor survival of these patients. As
such, while we found low rates of toxicity, it remains
possible that patient survival was too short for late toxi-
cities to manifest. These findings are encouraging as they
indicate that SRT/SRS for brainstem metastases is a ra-
ther safe treatment despite the theoretical potential for
serious side effects.
The majority of studies have assessed the use of
Gamma Knife for management of brainstem metastases,
Our study represents the third report, to our knowledge,
examining the use of linac-based platforms for treatment
of these lesions. As Table 2 demonstrates, rates of local
control, survival and adverse effects are comparable be-
tween studies using Gamma Knife or linac platforms
suggesting that linac systems may be utilized safely and
effectively for treatment of brainstem metastases.
Interestingly, our study found that treatment with
higher dose predicts improved survival but we were un-
able to make any claim regarding local control as only a
single local failure was detected in our cohort. As such, it
remains possible that improved local control resulting
from higher overall dose is contributing to longer sur-
vival but our study was not sufficiently powered to make
this conclusion. The low rates of toxicities associated
with this therapy suggest that fractionation of therapy
may appropriately mitigate adverse effects and allow for
safer treatment with higher dosing which may addition-
ally contribute to improved rates of survival. In particular
patients with smaller lesions and well controlled extra-
cranial disease may benefit most from the use of higher
dosing (≥20 Gy). Fractionation may be considered for lar-
ger brain metastases given radiobiological advantages as
well as safety concerns for sensitive adjacent structures.
In light of our findings, we do not believe that conser-
vative management with medical therapy alone is
recommended for patients with brainstem metastases as
SRT/SRS confers a benefit in both local control and sur-
vival. Furthermore, we have demonstrated that the risks
associated with SRT/SRS in patients with poor prognosis
are minimal due to the accuracy and conformal nature
of the treatment as well as the fact that shorter survival
may not allow late toxicities to manifest. Indeed, distant
intracranial failure remains an issue, as 47% of our
Table 2 Prior studies examining SRS for brainstem metastases
Study Treatment
modality
Patients,
n
Mean
age, y
Median tumor
volume, mL
Median
prescribed
SRS Dose, Gy
Median
survival,
mo
Local tumor
control, %
Factors associated
With shorter
survival
Complication
rate
Huang et al. [8] Gamma Knife 26 56 1.1 16 9 95 Presence of active
extracranial disease
27%
Shuto et al. [13] Gamma Knife 25 57.1 2.1 (mean) 13 (mean) 4.9 77 N/A 8%
Fuentes et al. [6] Gamma Knife 28 57.7 2.1 (mean) 19.6 (mean) 12 92 N/A 0%
Yen et al. [14] Gamma Knife 53 57.3 2.8 (mean) 17.6 (mean) 11 87 Presence of
extracranial
disease
0%
Hussain et al. [9] Gamma Knife 22 60 (median) 0.9 16 8.5 100 N/A 5%
Kased et al. [10] Gamma Knife 42 55 (median) 0.26 16 9 85 Multiple metastases,
melanoma primary
10%
Lorenzoni
et al. [15]
Gamma Knife 25 54 0.6 (mean) 20 (mean) 11.1 95 KPS <80,
uncontrolled
primary tumor,
radiotherapy,
SRS< 18 Gy
0%
Koyfman
et al. [11]
Gamma Knife 43 59 (median) 0.37 15 5.8 85 Lower KPS, larger
tumor volume,
SIR, GPA
12%
Hatiboglu
et al. [7]
Linac-based
SRT/SRS
60 61 (median) 1 15 4.2 76 Tumor volume
≥4 mL, male sex
20%
Lin et al. [12] Linac-based
SRT/SRS
45 59.9 0.4 14 11.6 91 Lower KPS 4%
Present Study Linac-based
SRT/SRS
36 61 0.94 17 3 93 Lower GPA, lower
prescription dose,
fewer fractions
8%
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patients had multiple brain metastases again highlighting
the advanced nature of the presenting disease. Unfortu-
nately, given the retrospective nature of our study, we
can only speculate on the potential survival of this co-
hort were they to be managed conservatively without
SRT/SRS. Still, with the favorable risk-benefit profile, we
believe that SRT/SRS is appropriately indicated in
patients with brainstem metastases and advanced intra-
cranial and/or extracranial disease.
Other limitations of our study include our sample
number which was somewhat small, preventing certain
comparisons due to power limitations. Additionally,
while only 52% of patients in our study had follow-up
imaging available for review, this is likely due, in part, to
the poor prognosis in this particular group of patients.
The number of studies examining SRT/SRS for brain-
stem metastases is steadily increasing. A meta-analysis
would more definitively determine the efficacy and safety
of SRT/SRS in this setting and more clearly define opti-
mal treatment regimens and prognostic factors.Conclusions
SRT/SRS for brainstem metastases is safe and achieves
a high rate of local control; therefore, often evadingprogressive disease and neurologic death. Patients treated
with higher prescription dose and a fractionated regimen
demonstrate increased survival. GPA score may be an ap-
propriate prognostic measure of estimated survival that
has now been corroborated by multiple reports. Despite
this approach, prognosis remains poor and distant intra-
cranial control remains an issue, even in patients who
were previously treated with WBRT.
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